Please provide your email address to receive an email when new articles are posted on . The integration of second-generation anti-vascular endothelial growth factor (VEGF) therapies into treatment ...

Abstract: NAnoscale Molecular Dynamics (NAMD) is a parallel molecular dynamics application that has been used to make breakthroughs in understanding the structure and dynamics of large biomolecular ...

A new biosimilar for aflibercept shows similar efficacy and safety in treating neovascular age-related macular degeneration (nAMD), enhancing patient access to treatment. A biosimilar to aflibercept ...

Researchers evaluated the efficacy, safety, and durability of the port-delivery system with ranibizumab in real-world patients with neovascular age-related macular degeneration. The port-delivery ...

Susvimo is the only continuous delivery treatment to provide reliable, long-term vision outcomes in nAMD, the leading cause of vision loss in people over the age of 60 With two refills per year, ...

Aflibercept 8 mg improves anatomic and visual outcomes in eyes with neovascular age-related macular degeneration. Aflibercept 8 mg therapy has a number of advantages for patients with neovascular ...

Imagine waking up one morning and noticing that things just don’t look as clear as they once did. It’s a gradual change, blurry spots in your central vision or difficulty seeing fine details. For ...

为探究临床试验疾病活动标准对 nAMD 抗 VEGF 注射间隔的影响，研究发现两者差异显著，影响治疗决策。 # 临床试验疾病活动标准如何影响湿性年龄相关性黄斑变性治疗？ 在眼科疾病领域，年龄相关性黄斑变性（AMD）就像一个隐藏在暗处的 “视力杀手 ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Tyrosine kinase inhibitors (TKIs) are emerging as a ...

An international study led by Hamid Riazi-Esfahani, MD, found that the presence of biomarkers observed on optical coherence tomography (OCT) images at baseline may help predict changes in the visual ...

Korean investigators reported that faricimab (Vabysmo, Roche/Genentech) in a real-world setting works well for patients with neovascular age-related macular degeneration (nAMD) refractory to other ...

Faricimab targets VEGF-A and Ang-2, enhancing vascular stability and reducing inflammation in nAMD patients unresponsive to other treatments. Significant improvements in visual acuity, central ...